Related Experiment Video

Updated: Aug 12, 2026

Breast Milk Enhances Growth of Enteroids: An Ex Vivo Model of Cell Proliferation
09:02

Breast Milk Enhances Growth of Enteroids: An Ex Vivo Model of Cell Proliferation

Published on: February 15, 2018

Breastfeeding in phenylketonuria

K Motzfeldt1, R Lilje, G Nylander

  • 1Department of Pediatric Research, The National Hospital, Oslo, Norway. kristina.motzfelt@klinmed.uio.no

Acta Paediatrica (Oslo, Norway : 1992). Supplement
|January 8, 2000
PubMed

Insights

Early dietary intervention for infants with phenylketonuria (PKU) using a phenylalanine-free substitute alongside breastfeeding promotes normal growth. This treatment approach effectively normalizes serum phenylalanine levels within days, supporting healthy development in affected newborns.

Area of Science:

  • Metabolic disorders
  • Pediatric nutrition
  • Genetics

Background:

  • Classical phenylketonuria (PKU) is a rare genetic disorder.
  • Early diagnosis and treatment are crucial for preventing neurological damage.
  • Norway has a centralized treatment system for PKU infants.

Purpose of the Study:

  • To evaluate the effectiveness of early dietary intervention in infants with classical phenylketonuria.
  • To assess the impact of breastfeeding combined with a phenylalanine-free protein substitute on infant growth and development.
  • To determine the time required for serum phenylalanine normalization.

Main Methods:

  • Retrospective analysis of 83 infants diagnosed with classical PKU in Norway since 1979.
  • Dietary treatment initiated between 5 and 33 days of age.
  • Monitoring of serum phenylalanine levels and infant growth parameters (weight, length, head circumference).

Main Results:

  • Seventy-four infants were breastfed with a phenylalanine-free protein substitute.
  • Dietary treatment commenced at a mean age of 14 days.
  • Serum phenylalanine normalization (below 400 pmol/l) achieved in a mean of 8 days.
  • Breastfeeding duration averaged 7 months.
  • Infant growth parameters remained within normal ranges.

Conclusions:

  • Early initiation of dietary treatment for phenylketonuria is effective.
  • Combined breastfeeding and phenylalanine-free protein substitute supports normal growth in PKU infants.
  • Centralized treatment facilitates consistent management and monitoring.

More Related Videos

A Common Marmoset Model of Mother-Infant Intervention for Breastfeeding Disorders in the Presence of Paternal Inhibition and Maternal Neglect05:04

A Common Marmoset Model of Mother-Infant Intervention for Breastfeeding Disorders in the Presence of Paternal Inhibition and Maternal Neglect

Published on: September 22, 2023

An Efficient Single-Person Technique for Milk Sampling from Laboratory Mice04:56

An Efficient Single-Person Technique for Milk Sampling from Laboratory Mice

Published on: March 28, 2025

Related Concept Videos

Overview of Protein Metabolism01:21

Overview of Protein Metabolism

Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...